Inhibition of CCL2 signaling in combination with Docetaxel treatment has profound inhibitory effects on prostate cancer growth in bone

International Journal of Molecular Sciences

Volumn 14, Issue 5, 2013, Pages 10483-10496

  Kirk, Peter S ^a   Koreckij, Theodore ^a,b   Nguyen, Holly M ^a   Brown, Lisha G ^a   Snyder, Linda A ^c   Vessella, Robert L ^a   Corey, Eva ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Bone metastases; CCL2; Chemokine; Docetaxel; Prostate cancer

Indexed keywords

CHEMOKINE RECEPTOR CCR2 ANTAGONIST; DOCETAXEL; MONOCYTE CHEMOTACTIC PROTEIN 1; ANTINEOPLASTIC AGENT; NEUTRALIZING ANTIBODY; PROSTATE SPECIFIC ANTIGEN; TAXOID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE METASTASIS; BONE TURNOVER; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER LOCALIZATION; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; MALE; MOUSE; NONHUMAN; PROSTATE CANCER; SIGNAL TRANSDUCTION; TUMOR INVASION; UPREGULATION; WEIGHT CHANGE; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; BODY WEIGHT; BONE NEOPLASMS; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; METABOLISM; PATHOLOGY; PROSTATIC NEOPLASMS; SCID MOUSE; SECONDARY; SURVIVAL; TIME; TREATMENT OUTCOME; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BODY WEIGHT; BONE DENSITY; BONE NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMOKINE CCL2; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE, SCID; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TAXOIDS; TIME FACTORS; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84878234297     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms140510483     Document Type: Article

References (36)

1. Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Thun, M.J. Cancer statistics, 2009. CA Cancer J. Clin. 2009, 59, 225-249.
2. Petrylak, D. Therapeutic options in androgen-independent prostate cancer: Building on docetaxel. BJU Int. 2005, 96, 41-46.
3. Armstrong, A.J.; Garrett-Mayer, E.S.; Yang, Y.C.; de Wit, R.; Tannock, I.F.; Eisenberger, M. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: A TAX327 study analysis. Clin. Cancer Res. 2007, 13, 6396-6403.
4. Berthold, D.R.; Pond, G.R.; Soban, F.; de Wit, R.; Eisenberger, M.; Tannock, I.F. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study. J. Clin. Oncol. 2008, 26, 242-245.
5. Tannock, I.F.; de Wit, R.; Berry, W.R.; Horti, J.; Pluzanska, A.; Chi, K.N.; Oudard, S.; Theodore, C.; James, N.D.; Turesson, I.; et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 2004, 351, 1502-1512.
6. Lu, Y.; Chen, Q.; Corey, E.; Xie, W.; Fan, J.; Mizokami, A.; Zhang, J. Activation of MCP-1/CCR2 axis promotes prostate cancer growth in bone. Clin. Exp. Metastasis 2009, 26, 161-169.
7. Shirotake, S.; Miyajima, A.; Kosaka, T.; Tanaka, N.; Kikuchi, E.; Mikami, S.; Okada, Y.; Oya, M. Regulation of monocyte chemoattractant protein-1 through angiotensin II type 1 receptor in prostate cancer. Am. J. Pathol. 2012, 180, 1008-1016.
8. Sun, T.; Mary, L.G.; Oh, W.K.; Freedman, M.L.; Pomerantz, M.; Pienta, K.J.; Kantoff, P.W. Inherited variants in the chemokine CCL2 gene and prostate cancer aggressiveness in a Caucasian cohort. Clin. Cancer Res. 2011, 17, 1546-1552.
9. Shi, C.L.; Yu, C.H.; Zhang, Y.; Zhao, D.; Chang, X.H.; Wang, W.H. Monocyte chemoattractant protein-1 modulates invasion and apoptosis of PC-3M prostate cancer cells via regulating expression of VEGF, MMP9 and caspase-3. Asian Pac. J. Cancer Prev. 2011, 12, 555-559.
10. Mizutani, K.; Sud, S.; McGregor, N.A.; Martinovski, G.; Rice, B.T.; Craig, M.J.; Varsos, Z.S.; Roca, H.; Pienta, K.J. The chemokine CCL2 increases prostate tumor growth and bone metastasis through macrophage and osteoclast recruitment. Neoplasia 2009, 11, 1235-1242.
11. Loberg, R.D.; Ying, C.; Craig, M.; Day, L.L.; Sargent, E.; Neeley, C.; Wojno, K.; Snyder, L.A.; Yan, L.; Pienta, K.J. Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. Cancer Res. 2007, 67, 9417-9424.
12. Craig, M.; Ying, C.; Loberg, R.D. Co-inoculation of prostate cancer cells with U937 enhances tumor growth and angiogenesis in vivo. J. Cell Biochem. 2008, 103, 1-8.
13. Li, X.; Loberg, R.; Liao, J.; Ying, C.; Snyder, L.A.; Pienta, K.J.; McCauley, L.K. A destructive cascade mediated by CCL2 facilitates prostate cancer growth in bone. Cancer Res. 2009, 69, 1685-1692.
14. Fulton, A.M. The chemokine receptors CXCR4 and CXCR3 in cancer. Curr. Oncol. Rep. 2009, 11, 125-131.
15. Leber, M.F.; Efferth, T. Molecular principles of cancer invasion and metastasis (review). Int. J. Oncol. 2009, 34, 881-895.
16. Rubin, J.B. Chemokine signaling in cancer: One hump or two? Semin. Cancer Biol. 2009, 19, 116-122.
17. Wu, X.; Lee, V.C.; Chevalier, E.; Hwang, S.T. Chemokine receptors as targets for cancer therapy. Curr. Pharm. Des. 2009, 15, 742-757.
18. Waugh, D.J.; Wilson, C.; Seaton, A.; Maxwell, P.J. Multi-faceted roles for CXC-chemokines in prostate cancer progression. Front. Biosci. 2008, 13, 4595-4604.
19. Vindrieux, D.; Escobar, P.; Lazennec, G. Emerging roles of chemokines in prostate cancer. Endocr. Relat Cancer 2009, 16, 663-673.
20. Lu, Y.; Cai, Z.; Galson, D.L.; Xiao, G.; Liu, Y.; George, D.E.; Melhem, M.F.; Yao, Z.; Zhang, J. Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion. Prostate 2006, 66, 1311-1318.
21. Lu, Y.; Cai, Z.; Xiao, G.; Keller, E.T.; Mizokami, A.; Yao, Z.; Roodman, G.D.; Zhang, J. Monocyte chemotactic protein-1 mediates prostate cancer-induced bone resorption. Cancer Res. 2007, 67, 3646-3653.
22. Loberg, R.D.; Ying, C.; Craig, M.; Yan, L.; Snyder, L.A.; Pienta, K.J. CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration. Neoplasia 2007, 9, 556-562.
23. Izhak, L.; Wildbaum, G.; Zohar, Y.; Anunu, R.; Klapper, L.; Elkeles, A.; Seagal, J.; Yefenof, E.; yalon-Soffer, M.; Karin, N. A novel recombinant fusion protein encoding a 20-amino acid residue of the third extracellular (E3) domain of CCR2 neutralizes the biological activity of CCL2. J. Immunol. 2009, 183, 732-739.
24. Zollo, M.; di Dato, V.; Spano, D.; de Martino, D.; Liguori, L.; Marino, N.; Vastolo, V.; Navas, L.; Garrone, B.; Mangano, G.; et al. Targeting monocyte chemotactic protein-1 synthesis with bindarit induces tumor regression in prostate and breast cancer animal models. Clin. Exp. Metastasis 2012, 29, 585-601.
25. Zhang, J.; Lu, Y.; Pienta, K.J. Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth. J. Natl. Cancer Inst. 2010, 102, 522-528.
26. Zhang, J.; Patel, L.; Pienta, K.J. CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. Cytokine Growth Factor Rev. 2010, 21, 41-48.
27. Zhang, J.; Patel, L.; Pienta, K.J. Targeting chemokine (C-C motif) ligand 2 (CCL2) as an example of translation of cancer molecular biology to the clinic. Prog. Mol. Biol. Transl. Sci. 2010, 95, 31-53.
28. Binder, N.B.; Niederreiter, B.; Hoffmann, O.; Stange, R.; Pap, T.; Stulnig, T.M.; Mack, M.; Erben, R.G.; Smolen, J.S.; Redlich, K. Estrogen-dependent and C-C chemokine receptor-2-dependent pathways determine osteoclast behavior in osteoporosis. Nat. Med. 2009, 15, 417-424.
29. Qian, D.Z.; Rademacher, B.L.; Pittsenbarger, J.; Huang, C.Y.; Myrthue, A.; Higano, C.S.; Garzotto, M.; Nelson, P.S.; Beer, T.M. CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicity. Prostate 2010, 70, 433-442.
30. Pienta, K.J.; Machiels, J.P.; Schrijvers, D.; Alekseev, B.; Shkolnik, M.; Crabb, S.J.; Li, S.; Seetharam, S.; Puchalski, T.A.; Takimoto, C.; et al. Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer. Invest. New Drugs 2012, 31, 760-768.
31. Thalmann, G.N.; Anezinis, P.E.; Chang, S.; Zhau, H.E.; Kim, E.E.; Hopwood, V.L.; Pathak, S.; von Eschenbach, A.C.; Chung, L.W.K. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res. 1994, 54, 2577-2581.
32. Pfitzenmaier, J.; Quinn, J.E.; Odman, A.M.; Zhang, J.; Keller, E.T.; Vessella, R.L.; Corey, E. Characterization of C4-2 prostate cancer bone metastases and their response to castration. J. Bone Miner. Res. 2003, 18, 1882-1888.
33. Corey, E.; Quinn, J.E.; Bladou, F.; Brown, L.G.; Roudier, M.P.; Brown, J.M.; Buhler, K.R.; Vessella, R.L. Establishment and characterization of osseous prostate cancer models: Intra-tibial injection of human prostate cancer cells. Prostate 2002, 52, 20-33.
34. Qian, B.Z.; Li, J.; Zhang, H.; Kitamura, T.; Zhang, J.; Campion, L.R.; Kaiser, E.A.; Snyder, L.A.; Pollard, J.W. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 2011, 475, 222-225.
35. Sarafi, M.N.; Garcia-Zepeda, E.A.; MacLean, J.A.; Charo, I.F.; Luster, A.D. Murine monocyte chemoattractant protein (MCP)-5: A novel CC chemokine that is a structural and functional homologue of human MCP-1. J. Exp. Med. 1997, 185, 99-109.
36. Corey, E.; Quinn, J.E.; Buhler, K.R.; Nelson, P.S.; Macoska, J.A.; True, L.D.; Vessella, R.L. LuCaP 35: A new model of prostate cancer progression to androgen independence. Prostate 2003, 55, 239-246.